Parameter
| Biomarker | CTLA-4 | Full name | Cytotoxic T-Lymphocyte-Associated Protein 4 | Molecular Type | protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | assessment of immune status and prognosis | ||
| Disease | Multiple Myeloma (MM) | Disease Subtypes | / | ||
| Organ | Bone marrow, Serum | Test Sample / Technology Platform | serum、marrow | ||
| Pathobiological Mechanisms | CTLA-4 overexpression leads to Treg accumulation and weakens anti-tumor immunity | ||||
| Clinical Availability Status | research verification | ||||
| Notes and Dynamics | CTLA-4 gene polymorphisms (rs231775, rs3087243) are associated with myeloma susceptibility and immune therapy efficacy, showing promise as potential biomarkers for personalized medicine. | ||||